Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice

Center for Vaccine Research,a Graduate Program in Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Journal of Virology (Impact Factor: 4.44). 11/2011; 86(3):1500-13. DOI: 10.1128/JVI.06034-11
Source: PubMed

ABSTRACT The Spanish influenza virus pandemic of 1918 was responsible for 40 million to 50 million deaths and is antigenically similar to the swine lineage 2009 pandemic influenza virus. Emergence of the 2009 pandemic from swine into humans has raised the possibility that low levels of cross-protective immunity to past shared epitopes could confer protection. In this study, influenza viruslike particles (VLPs) were engineered to express the hemagglutinin (HA) and genes from the 1918 influenza virus to evaluate the duration of cross-protection to the H1N1 pandemic strain by vaccinating young mice (8 to 12 weeks) and then allowing the animals to age to 20 months. This immunity was long lasting, with homologous receptor-blocking antibodies detected throughout the lifespan of vaccinated mice. Furthermore, the 1918 VLPs fully protected aged mice from 2009 pandemic H1N1 virus challenge 16 months after vaccination. Histopathological assessment showed that aged vaccinated mice had significant protection from alveolar infection but less protection of the bronchial tissue than adult vaccinated mice. Additionally, passive transfer of immune serum from aged vaccinated mice resulted in protection from death but not morbidity. This is the first report describing the lifelong duration of cross-reactive immune responses elicited by a 1918 VLP vaccine in a murine model. Importantly, these lifelong immune responses did not result in decreased total viral replication but did prevent infection of the lower respiratory tract. These findings show that immunity acquired early in life can restrict the anatomical location of influenza viral replication, rather than preventing infection, in the aged.

Download full-text


Available from: Ted M Ross, Aug 19, 2014
40 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Emerging and re-emerging infectious diseases are increasing throughout the world and highly pathogenic influenza is among those that pose a significant threat to mankind. Pandemic outbreaks of influenza are caused by the emergence of a highly pathogenic and transmissible virus to which the human population is immunologically naïve. Ongoing outbreaks of highly pathogenic avian influenza of the H5N1 subtype are of particular concern because of the high mortality rate (>60%) and novel subtype. Vaccines are considered the most effective way to prevent the morbidity and mortality associated with pandemic influenza and therefore developing an H5N1 vaccine is a public health priority. One of the hurdles facing H5N1 vaccine development is the antigenic diversity of the subtype as evidenced by the identification of ten phylogenetic clades. To overcome the challenge of antigenic diversity, a centralized hemagglutinin was developed and termed computationally optimized broadly reactive antigen (COBRA). The COBRA HA sequence was based upon HA amino acid sequences from clade 2 H5N1 human infections and the expressed protein retained the ability to bind the receptor, as well as mediate particle fusion. COBRA virus-like particle (VLP) vaccines elicited broadly reactive receptor blocking antibodies in multiple animal species: mice, ferrets and non-human primates. The reactivity profile was broader than that elicited by primary isolate-based vaccines given in either monovalent or polyvalent formulations. Although all vaccinated animals were protected from severe disease and death from experimental infection with highly pathogenic H5N1 virus, animals receiving the COBRA vaccine had reduced peak virus replication and cleared the infection more rapidly. COBRA vaccines were shown to be superior to primary isolate-based vaccines with both a broader antibody profile and more efficient protective efficacy. The development of COBRA resulted in a novel antigen generation methodology that is applicable to both pandemic and seasonal influenza.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The H1N1 2009 influenza virus (H1N1pdm09) pandemic had several unexpected features, including low morbidity and mortality in older populations. We performed in-depth evaluation of antibody responses generated following H1N1pdm09 infection of naïve ferrets and of 130 humans ranging from the very young (0 to 9 years old) to the very old (70 to 89 years old). In addition to hemagglutination inhibition (HI) titers, we used H1N1pdm09 whole-genome-fragment phage display libraries (GFPDL) to evaluate the antibody repertoires against internal genes, hemagglutinin (HA), and neuraminidase (NA) and also measured antibody affinity for antigenic domains within HA. GFPDL analyses of H1N1pdm09-infected ferrets demonstrated gradual development of antibody repertoires with a focus on M1 and HA1 by day 21 postinfection. In humans, H1N1pdm09 infection in the elderly (>70 years old) induced antibodies with broader epitope recognition in both the internal genes and the HA1 receptor binding domain (RBD) than for the younger age groups (0 to 69 years). Importantly, post-H1N1 infection serum antibodies from the elderly demonstrated substantially higher avidity for recombinant HA1 (rHA1) (but not HA2) than those from younger subjects (50% versus <22% 7 M urea resistance, respectively) and lower antibody dissociation rates using surface plasmon resonance. This is the first study in humans that provides evidence for a qualitatively superior antibody response in the elderly following H1N1pdm09 infection, indicative of recall of long-term memory B cells or long-lived plasma cells. These findings may help explain the age-related morbidity and mortality pattern observed during the H1N1pdm09 pandemic.
    Journal of Virology 02/2012; 86(10):5515-22. DOI:10.1128/JVI.07085-11 · 4.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Individuals <60 years of age had the lowest incidence of infection with ∼25% of these people having pre-existing, cross-reactive antibodies to novel 2009 H1N1 influenza. Many people >60 years old also had pre-existing antibodies to novel H1N1. These observations are puzzling because the seasonal H1N1 viruses circulating during the last 60 years were not antigenically similar to novel H1N1. We therefore hypothesized that a sequence of exposures to antigenically different seasonal H1N1 viruses could elicit an antibody response that protects against novel 2009 H1N1. Ferrets were pre-infected with seasonal H1N1 viruses and assessed for cross-reactive antibodies to novel H1N1. Serum from infected ferrets was assayed for cross-reactivity to both seasonal and novel 2009 H1N1 strains. These results were compared to ferrets that were sequentially infected with H1N1 viruses isolated prior to 1957 or more recently isolated viruses. Following seroconversion, ferrets were challenged with novel H1N1 influenza virus and assessed for viral titers in the nasal wash, morbidity, and mortality. There was no HAI cross-reactivity in ferrets infected with any single seasonal H1N1 influenza viruses with limited protection to challenge. However, sequential H1N1 influenza infections reduced the incidence of disease and elicited cross-reactive antibodies to novel H1N1 isolates. The amount and duration of virus shedding, and the frequency of transmission following novel H1N1 challenge, were reduced. Exposure to multiple seasonal H1N1 influenza viruses, not any single H1N1 influenza virus, elicits a breadth of antibodies that neutralize novel H1N1, even though the host was never exposed to the novel H1N1 influenza viruses.
    Journal of Virology 10/2012; 87(3). DOI:10.1128/JVI.02257-12 · 4.44 Impact Factor
Show more